Private Label Skin Care, Inc.

Warning LetterOpen

Mr. Samuel D. Raoof President/CEO Private Label Skin Care, Inc. 8200 Remmet Ave. Canoga Park , CA 91304-4156 United StatesFEI 3015274499Issued Dec 18, 2025Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3015274499.

Violations2

Issue DateDec 18, 2025

Product TypeDrugs

StatusOpen

Letter Details

Firm: Private Label Skin Care, Inc.
Location: Mr. Samuel D. Raoof President/CEO Private Label Skin Care, Inc. 8200 Remmet Ave. Canoga Park , CA 91304-4156 United States
FEI Number: 3015274499
Country: United States
Issue Date: December 18, 2025
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

Private Label Skin Care, Inc. was warned for manufacturing over-the-counter drug products in violation of Current Good Manufacturing Practice (CGMP) regulations, rendering their products adulterated. The FDA inspection from June 16-23, 2025 identified significant violations including failure to establish an adequate quality control unit and failure to submit drug listings for at least 21 human OTC drugs to the FDA's electronic Drug Registration and Listing System as required by law. These unlisted drugs were deemed misbranded and their introduction into interstate commerce was prohibited. The company's manufacturing methods, facilities, and controls did not conform to required pharmaceutical standards.

Private Label Skin Care, Inc. FDA Warning Letter, December 18, 2025